Advances of anti-diabetic drugs based on new targets
10.11665/j.issn.1000-5048.20150202
- VernacularTitle:基于新靶点的抗糖尿病药物研究进展
- Author:
Xinning WANG
1
;
Bin XU
;
Jinpei ZHOU
;
Huibin ZHANG
Author Information
1. 中国药科大学江苏省抗代谢性疾病药物重点实验室
- Publication Type:Journal Article
- Keywords:
type 2 diabetes;
new target;
insulin;
β cell;
research advance;
GPR119;
GPR40;
GSK3β
- From:
Journal of China Pharmaceutical University
2015;46(2):141-152
- CountryChina
- Language:Chinese
-
Abstract:
With the deepening of research, different new anti-diabetic drug targets have been discovered and reported, several categories of anti-diabetic drugs(linagliptin, exenatide, dapagliflozin, etc. )have been brought to the market and some new drugs acting on different targets are in late-stage clinical trials. All these progresses provide new means for overcoming diabetes. GPR119, GPR120, GPR40, AMPK, apelin receptor and GSK3β are anti-diabetic targets with great research values in current days and the future. This article reviews the mechanisms, drugs and research advances with respect to the above-mentioned targets.
